U. Rix

发表

Target profiling of small molecules by chemical proteomics.

G. Superti-Furga, U. Rix, 2009, Nature chemical biology.

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.

Forest M White, Giulio Superti-Furga, Florian P Breitwieser, 2012, Nature chemical biology.

Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate.

U. Rix, J. Rohr, T. A. Macky, 2002, Journal of medicinal chemistry.

Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.

S. Eschrich, U. Rix, E. Haura, 2019, Cell chemical biology.

Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells*

U. Rix, E. Haura, B. Kuenzi, 2018, Molecular & Cellular Proteomics.

Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies

Eric B Haura, Uwe Rix, U. Rix, 2015, Cancer Immunology Research.

An immunoproteomic approach to characterize the CAR interactome and signalosome

U. Rix, E. Haura, B. Kuenzi, 2019, Science Signaling.

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

U. Rix, G. Wright, W. D. Cress, 2019, FEBS open bio.

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

Bin Fang, Steven Eschrich, Giulio Superti-Furga, 2010, Nature chemical biology.

Acid elution and one-dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography.

Florian P Breitwieser, Uwe Rix, Jacques Colinge, 2009, Journal of proteome research.

Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics

G. Superti-Furga, K. Bennett, S. Ficarro, 2014, Molecular Cancer Therapeutics.

A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.

G. Superti-Furga, K. Bennett, A. Stukalov, 2013, Journal of proteome research.

Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.

U. Rix, E. Haura, J. Koomen, 2018, Journal of proteome research.

Unraveling the rewired network

U. Rix, B. Kuenzi, V. Palve, 2018, Nature Chemical Biology.

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer

G. Superti-Furga, U. Rix, B. Kuenzi, 2017, Oncotarget.

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions

Y. Kluger, D. Wheeler, J. Minna, 2016, Oncotarget.

Nilotinib-induced vasculopathy : identification of vascular 1 endothelial cells as a primary target site 2 3 4

G. Superti-Furga, U. Rix, P. Valent, 2017 .

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

G. Superti-Furga, U. Rix, P. Valent, 2017, Leukemia.

Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.

U. Rix, K. Smalley, E. Haura, 2015, Methods.

Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine.

M. Mildner, U. Rix, M. Posch, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis.

U. Rix, J. Rohr, M. Nur-E-Alam, 2003, Journal of the American Chemical Society.

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells

Bin Fang, John M. Koomen, Steven A. Eschrich, 2013, Proceedings of the National Academy of Sciences.

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

U. Rix, A. Marusyk, C. Lovly, 2022, Science Signaling.

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

G. Superti-Furga, U. Rix, W. Pickl, 2007 .

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer

Jiqiang Yao, D. Coppola, U. Rix, 2018, Molecular Cancer Therapeutics.

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

U. Rix, G. Wright, E. Haura, 2014, ACS chemical biology.

Selective serotonin reuptake inhibitors: a new modality for the treatment of lymphoma/leukaemia?

G. Superti-Furga, H. Sitte, U. Rix, 2007, Biochemical pharmacology.

Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML

A. Karsan, U. Rix, J. Lancet, 2022, bioRxiv.

Selective serotonin reuptake inhibitors—A new modality for the treatment of lymphoma/leukaemia?

G. Superti-Furga, H. Sitte, U. Rix, 2007 .

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines

U. Rix, G. Wright, W. D. Cress, 2021, PloS one.

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

G. Superti-Furga, K. Bennett, O. Hantschel, 2010, Leukemia.

Modification of post-PKS tailoring steps through combinatorial biosynthesis.

U. Rix, J. Rohr, C. Fischer, 2002, Natural product reports.

Functional Analyses of Oxygenases in Jadomycin Biosynthesis and Identification of JadH as a Bifunctional Oxygenase/Dehydrase*

U. Rix, J. Rohr, D. Hoffmeister, 2005, Journal of Biological Chemistry.

Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition

S. Chavan, U. Rix, E. Haura, 2021, Clinical Cancer Research.

Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Yi Liao, Uwe Rix, Vinayak Palve, 2020, Seminars in cancer biology.

Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target.

U. Rix, E. Schönbrunn, E. Haura, 2023, ACS chemical biology.

Targeting a cell state common to triple-negative breast cancers

Markus K. Muellner, G. Superti-Furga, K. Bennett, 2015, Molecular systems biology.

Identification of the function of gene lndM2 encoding a bifunctional oxygenase-reductase involved in the biosynthesis of the antitumor antibiotic landomycin E by Streptomyces globisporus 1912 supports the originally assigned structure for landomycinone.

U. Rix, J. Rohr, M. Nur-E-Alam, 2005, The Journal of organic chemistry.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

A. Jimeno, U. Rix, M. Varella‐Garcia, 2017, Cancer research.

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

G. Superti-Furga, O. Hantschel, U. Rix, 2008, Leukemia & lymphoma.

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Gerhard Dürnberger, Oliver Hantschel, Giulio Superti-Furga, 2007, Blood.

Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mi

U. Rix, J. Rohr, C. Méndez, 2002, Journal of the American Chemical Society.

Cytotoxic Activities of New Jadomycin Derivatives

U. Rix, J. Rohr, Lixia Zhao, 2005, The Journal of Antibiotics.

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

G. Superti-Furga, K. Bennett, O. Hantschel, 2007, Proceedings of the National Academy of Sciences.

Generation of new landomycins by combinatorial biosynthetic manipulation of the LndGT4 gene of the landomycin E cluster in S. globisporus.

U. Rix, J. Rohr, C. Méndez, 2004, Chemistry & biology.

The Oxidative Ring Cleavage in Jadomycin Biosynthesis: A Multistep Oxygenation Cascade in a Biosynthetic Black Box

U. Rix, J. Rohr, L. Vining, 2005, Chembiochem : a European journal of chemical biology.

An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B

G. Superti-Furga, K. Bennett, A. Stukalov, 2011, Molecular Cancer Therapeutics.

Kinases A and B Vulnerability of Ewing ' s Sarcoma to Combined Inhibition of Aurora An Integrated Chemical Biology Approach Identifies Specific

G. Superti-Furga, K. Bennett, A. Stukalov, 2011 .

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.

U. Rix, A. Monteiro, G. Wright, 2016, Cell chemical biology.

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.

U. Rix, B. Kuenzi, N. Sumi, 2015, ACS chemical biology.

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

U. Rix, K. Smalley, H. Lawrence, 2017, Molecular oncology.

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation

Huan Yang, U. Rix, S. Sebti, 2014, Oncotarget.

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Bin Fang, Jamie K Teer, Eric B Haura, 2014, Cancer research.

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

U. Rix, A. Monteiro, G. Wright, 2016, Molecular Cancer Therapeutics.

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.

U. Rix, A. Monteiro, G. Wright, 2017, ACS chemical biology.

Dasatinib in solid tumors

U. Rix, E. Haura, Lori C. Kim, 2010, Expert opinion on investigational drugs.

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.

G. Superti-Furga, K. Bennett, R. Valenta, 2008, Blood.

Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeutics

U. Rix, E. Haura, M. Boutchueng-Djidjou, 2018, Expert review of proteomics.

A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib

Giulio Superti-Furga, Uwe Rix, Jacques Colinge, 2010, PLoS Comput. Biol..

The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesis.

U. Rix, J. Rohr, Keqian Yang, 2004, Journal of the American Chemical Society.

Urdamycin L: A Novel Metabolic Shunt Product that Provides Evidence for the Role of the urdM Gene in the Urdamycin A Biosynthetic Pathway of Streptomyces fradiae TÜ 2717

U. Rix, J. Rohr, D. Hoffmeister, 2003, Chembiochem : a European journal of chemical biology.

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

G. Superti-Furga, K. Bennett, O. Hantschel, 2009, Leukemia.

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Bin Fang, Steven Eschrich, Giulio Superti-Furga, 2013, Molecular systems biology.

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors.

Amanda R. Kulick, M. Berger, A. Drilon, 2020, Cancer discovery.

Polypharmacology-based ceritinib repurposing using integrated functional proteomics.

Bin Fang, Paul A Stewart, Brent M Kuenzi, 2017, Nature chemical biology.

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL

G. Superti-Furga, K. Bennett, J. Colinge, 2013, PloS one.

Novel Global Network Scores to Analyze Kinase Inhibitor Profiles

G. Superti-Furga, J. Colinge, U. Rix, 2010 .

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

G. Superti-Furga, E. Tschachler, U. Rix, 2009, European journal of clinical investigation.

PAXIP 1 potentiates the combination of WEE 1 inhibitor AZD 1775 and platinum agents in lung cancer Running title : PAXIP 1 potentiates WEE 1 inhibitor action

Brantley, U. Rix, A. Monteiro, 2016 .

Enhancing cognate target elution efficiency in gel-free chemical proteomics

G. Superti-Furga, K. Bennett, A. Stukalov, 2015 .

Systems biology analysis of protein‐drug interactions

Giulio Superti-Furga, Uwe Rix, Jacques Colinge, 2012, Proteomics. Clinical applications.

APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data.

Paul A Stewart, Brent M Kuenzi, Adam L Borne, 2016, Journal of proteome research.

Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach

U. Rix, E. Haura, G. Reuther, 2020, Proteomics.

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

U. Rix, J. Lancet, B. Kuenzi, 2019, Scientific Reports.

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

K. Tsai, U. Rix, B. Czerniecki, 2021, Cancer Immunology Research.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines

V. Sondak, U. Rix, K. Smalley, 2017, Molecular Cancer Therapeutics.

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma

Michael A. Durante, J. Licht, U. Rix, 2019, Clinical Cancer Research.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

G. Superti-Furga, K. Bennett, U. Rix, 2011, Blood.

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

U. Rix, E. Haura, 2014, Journal of the National Cancer Institute.

A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF

G. Superti-Furga, K. Bennett, S. Wagner, 2014, Oncogene.

Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling

U. Rix, R. Doebele, A. Tan, 2021, Molecular Pharmacology.

Pacritinib (PAC) Synergistically Potentiates Azacitidine (5AZA) Cytotoxicity in Chronic Myelomonocytic Leukemia (CMML)

U. Rix, E. Padron, A. List, 2015 .

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

G. Superti-Furga, K. Bennett, U. Rix, 2016, Leukemia.

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.

Michael S. Cohen, U. Rix, A. Monteiro, 2021, Cell chemical biology.

Rationally designed glycosylated premithramycins: hybrid aromatic polyketides using genes from three different biosynthetic pathways.

U. Rix, J. Rohr, A. Bechthold, 2002, Journal of the American Chemical Society.

The lipid phosphatase activity of PTEN dampens FRA1 expression via AKT/mTOR signaling to suppress melanoma

U. Rix, F. Karreth, E. Welsh, 2023, bioRxiv.

Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer

U. Rix, D. Marchion, H. Lawrence, 2022, The Journal of biological chemistry.

Function of glycosyltransferase genes involved in urdamycin A biosynthesis.

U. Rix, J. Rohr, D. Hoffmeister, 2000, Chemistry & biology.

MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.

U. Rix, K. Smalley, E. Haura, 2019, Cancer research.

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling

U. Rix, E. Haura, J. Koomen, 2016, Molecular Cancer Therapeutics.

Compound immobilization and drug-affinity chromatography.

G. Superti-Furga, U. Rix, M. Gridling, 2012, Methods in molecular biology.

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.

G. Superti-Furga, K. Bennett, O. Hantschel, 2007 .

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

U. Rix, J. Lancet, B. Kuenzi, 2019, Scientific Reports.

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors.

B. Taylor, M. Berger, A. Drilon, 2020, Cancer discovery.

Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.

U. Rix, R. Doebele, E. Haura, 2023, Cell chemical biology.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

A. Jimeno, U. Rix, R. Doebele, 2017, Cancer research.

MASPECTRAS 2: An integration and analysis platform for proteomic data

Zlatko Trajanoski, Jürgen Hartler, Uwe Rix, 2010, Proteomics.

Target Identi fi cation in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Pro fi ling

U. Rix, E. Haura, J. Koomen, 2016 .